G1 Therapeutics is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 100 staff and has a trailing 12-month revenue of around $58.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.13 |
|---|---|
| 52-week range | $1.08 - $7.19 |
| 50-day moving average | $4.62 |
| 200-day moving average | $3.73 |
| Wall St. target price | $7.15 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.13 from 2024-09-06
| 1 week (2024-08-30) | 0.28% |
|---|---|
| 1 month (2024-08-07) | 0.99% |
| 3 months (2024-06-07) | 136.88% |
| 6 months (2024-03-07) | 99.16% |
| 1 year (2023-09-07) | 329.52% |
|---|---|
| 2 years (2022-09-07) | -53.06% |
| 3 years (2021-09-07) | 15.25 |
| 5 years (2019-09-06) | 36.27 |
| Revenue TTM | $58.2 million |
|---|---|
| Gross profit TTM | $47.6 million |
| Return on assets TTM | -19.2% |
| Return on equity TTM | -109.01% |
| Profit margin | -76.93% |
| Book value | $0.47 |
| Market Capitalization | $375.1 million |
TTM: trailing 12 months
We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $1.08 up to $7.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 1.535. This would suggest that G1 Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
G1 Therapeutics, Inc. , a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.